Peter A. Singer

Q: What Schools Are Affiliated With Peter A. Singer

Peter A. Singer is affiliated with the following schools: Yale University, University of Chicago, University of Toronto, University of Pennsylvania, Harvard University

Peter A. Singer's AcademicInfluence.com Rankings

Peter A. Singer

Medical

#703

World Rank

#931

Historical Rank

#254

USA Rank

Public Health

#116

World Rank

#123

Historical Rank

#41

USA Rank

Epidemiology

#409

World Rank

#428

Historical Rank

#68

USA Rank

medical Degrees

Peter A. Singer

Philosophy

#2103

World Rank

#3667

Historical Rank

#789

USA Rank

Logic

#3960

World Rank

#5196

Historical Rank

#747

USA Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Peter A. Singer Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Peter Alexander Singer, OC, FRSC, is special advisor to the director general of the World Health Organization, and also adjunct professor of medicine at University of Toronto. From 2008-2018 Singer was chief executive officer of Grand Challenges Canada and Director of the Sandra Rotman Centre, University Health Network. From 1996-2006 Singer was director of the University of Toronto Joint Centre for Bioethics.

(See a Problem?)

Peter A. Singer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Grand challenges in global mental health (2011) (1723)
Quality end-of-life care: patients' perspectives. (1999) (1289)
Grand challenges in chronic non-communicable diseases (2007) (677)
One World: The Ethics of Globalization (2002) (473)
Bioethics for clinicians. (1996) (427)
Top ten biotechnologies for improving health in developing countries (2002) (355)
Grand Challenges in Global Health: Community Engagement in Research in Developing Countries (2007) (338)
Reconceptualizing advance care planning from the patient's perspective. (1998) (321)
Nanotechnology and the Developing World (2005) (320)
Moral heuristics. Commentaries. Author's reply (2005) (276)
Grand Challenges in Global Health (2003) (258)
The illusion of futility in clinical practice. (1989) (252)
Ethics of liver transplantation with living donors. (1989) (252)
Assessment of patient capacity to consent to treatment (1999) (245)
Sex or survival: trade-offs between quality and quantity of life. (1991) (241)
Ethics and SARS: lessons from Toronto (2003) (240)
Global health ethics: the rationale for mutual caring (2003) (226)
Priority setting: what constitutes success? A conceptual framework for successful priority setting (2009) (224)
‘Mind the gap’: science and ethics in nanotechnology (2003) (220)
Health Innovation Networks to Help Developing Countries Address Neglected Diseases (2005) (209)
Chinese seniors' perspectives on end-of-life decisions. (2001) (173)
Harnessing Genomics and Biotechnology to Improve Global Health Equity (2001) (155)
Setting priorities in health care organizations: criteria, processes, and parameters of success (2004) (152)
Priority setting for new technologies in medicine: qualitative case study (2000) (152)
Advance Care Planning as a Process: Structuring the Discussions in Practice (1995) (151)
Fairness, accountability for reasonableness, and the views of priority setting decision-makers. (2002) (150)
Euthanasia--a critique. (1990) (140)
Planning for the end of life (2000) (131)
A Strategy to Improve Priority Setting in Health Care Institutions (2003) (129)
Bioethics for clinicians: 1. Consent. (1996) (126)
Priority-setting decisions for new cancer drugs: a qualitative case study (2001) (121)
Pharmacogenetics and geographical ancestry: implications for drug development and global health (2005) (121)
Clinical ethics revisited (2001) (119)
Referral for dialysis in Ontario. (1995) (116)
Responsibilities in international research: a new look revisited (2010) (111)
Consensus guidelines on analgesia and sedation in dying intensive care unit patients (2002) (111)
Bioethics for clinicians: 6. Advance care planning. (1996) (110)
Quality end-of-life care: A global perspective (2002) (109)
Priority setting in hospitals: fairness, inclusiveness, and the problem of institutional power differences. (2005) (109)
Bone marrow transplantation for sickle cell disease. A study of parents' decisions. (1991) (108)
Innovative health service delivery models in low and middle income countries - what can we learn from the private sector? (2010) (106)
A new model of advance care planning: observations from people with HIV. (1999) (104)
Chinese health biotech and the billion-patient market (2008) (103)
Origins of the desire for euthanasia and assisted suicide in people with HIV-1 or AIDS: a qualitative study (2001) (98)
Top 10 health care ethics challenges facing the public: views of Toronto bioethicists (2005) (92)
Life-sustaining treatment preferences of hemodialysis patients: implications for advance directives. (1995) (90)
Clinical Medical Ethics (1990) (90)
India's health biotech sector at a crossroads (2007) (90)
Evidence, economics and ethics: resource allocation in health services organizations. (2005) (86)
Participation in health care priority-setting through the eyes of the participants (2002) (85)
Bioethics for clinicians: 3. Capacity. (1996) (81)
Rationing, patient preferences, and cost of care at the end of life. (1992) (79)
The scientific muscle of Brazil's health biotechnology (2004) (79)
Bioethics for clinicians: 13. Resource allocation. (1997) (77)
Nephrologists' experience with and attitudes towards decisions to forego dialysis. The End-Stage Renal Disease Network of New England. (1992) (76)
Global Health Challenges: The Need for an Expanded Discourse on Bioethics (2005) (76)
Ethics and economics: does programme budgeting and marginal analysis contribute to fair priority setting? (2006) (75)
Conclusions: promoting biotechnology innovation in developing countries (2004) (74)
Brazilian health biotech—fostering crosstalk between public and private sectors (2008) (72)
Priority setting in a hospital critical care unit: Qualitative case study* (2003) (72)
Quality end-of-life care. (2000) (72)
Performance‐based assessment of clinical ethics using an objective structured clinical examination (1996) (70)
Regenerative Medicine and the Developing World (2006) (70)
Cuba—innovation through synergy (2004) (68)
Priority setting in a hospital drug formulary: a qualitative case study and evaluation. (2003) (66)
Beyond Helsinki: a vision for global health ethics (2001) (66)
Teaching Clinical Ethics (1990) (65)
Priority-setting and hospital strategic planning: a qualitative case study (2003) (65)
Quality care at the end of life (2002) (64)
Bioethics for clinicians: 17. Conflict of interest in research, education and patient care. (1998) (63)
Genomic medicine and developing countries: creating a room of their own (2008) (62)
The next steps for genomic medicine: challenges and opportunities for the developing world (2008) (61)
Priority setting and cardiac surgery: a qualitative case study. (2007) (60)
Bioethics for clinicians: 7. Truth telling. (1997) (60)
Indian biotechnology—rapidly evolving and industry led (2004) (58)
Disease-specific advance directives (1994) (58)
Canadian outpatients and advance directives: poor knowledge and little experience but positive attitudes. (1993) (57)
Bioethics for clinicians: 25. Teaching bioethics in the clinical setting. (2001) (57)
Harnessing Nanotechnology to Improve Global Equity (2005) (56)
Scientific diasporas as an option for brain drain: re-circulating knowledge for development (2006) (55)
Stem cell research and transplantation: science leading ethics. (2004) (55)
Regenerative medicine: New opportunities for developing countries (2006) (54)
Priority setting for new technologies in medicine: A transdisciplinary study (2002) (54)
Genomics, public health and developing countries: the case of the Mexican National Institute of Genomic Medicine (INMEGEN) (2008) (54)
Family physicians' attitudes toward advance directives. (1992) (54)
Leadership and priority setting: the perspective of hospital CEOs. (2006) (52)
Interdisciplinary research: putting the methods under the microscope (2003) (52)
Ethics Committees and Consultants (1990) (51)
Medical ethics (2000) (51)
Health innovation in developing countries to address diseases of the poor (2005) (50)
Access to intensive care unit beds for neurosurgery patients: a qualitative case study (2003) (50)
Bioethics for clinicians: 16. Dealing with demands for inappropriate treatment. (1998) (49)
Evaluating priority setting success in healthcare: a pilot study (2010) (49)
Bioethics for clinicians: 2. Disclosure. (1996) (49)
Grand Challenges in Global Health: The Ethical, Social and Cultural Program (2007) (48)
Public opinion regarding end-of-life decisions: influence of prognosis, practice and process. (1995) (48)
The ethical assessment of innovative therapies: Liver transplantation using living donors (1990) (47)
Hospital priority setting with an appeals process: a qualitative case study and evaluation. (2005) (46)
Autonomy, liberalism and advance care planning. (1999) (46)
Cultivating regenerative medicine innovation in China. (2010) (45)
Grand Challenges in Global Health: Engaging Civil Society Organizations in Biomedical Research in Developing Countries (2007) (43)
Introduction: promoting global health through biotechnology (2004) (43)
Bioethics for clinicians: 4. Voluntariness. (1996) (42)
Clinical bioethics integration, sustainability, and accountability: the Hub and Spokes Strategy (2005) (42)
Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators (2012) (42)
South-South entrepreneurial collaboration in health biotech (2010) (42)
Health biotechnology in China—reawakening of a giant (2004) (41)
Accuracy of clinical impressions and Mini-Mental State Exam scores for assessing capacity to consent to major medical treatment. Comparison with criterion-standard psychiatric assessments. (1997) (40)
Capacity to Complete an Advance Directive (1993) (40)
The Indian and Chinese health biotechnology industries: potential champions of global health? (2008) (39)
Genetically engineered oil-eating microbes for bioremediation: Prospects and regulatory challenges (2010) (39)
Equipoise and the ethics of segmental liver transplantation. (1988) (39)
Small but tenacious: South Africa's health biotech sector (2009) (38)
Hospital policy on appropriate use of life-sustaining treatment (2001) (38)
Scientific Diasporas (2006) (38)
The HIV-specific advance directive (1997) (38)
Clinical ethics consultation: Godsend or "God squad"? (1988) (37)
Biotechnology and the UN's Millennium Development Goals (2003) (37)
How can developing countries harness biotechnology to improve health? (2007) (37)
South Africa—blazing a trail for African biotechnology (2004) (37)
'Relief of oppression': An organizing principle for researchers' obligations to participants in observational studies in the developing world (2010) (37)
Public engagement on global health challenges (2008) (37)
Ethics of liver transplantation with living donors (1990) (36)
Public Opinion Regarding Consent to Treatment (1993) (36)
Advance directives: Are they an advance? (1992) (36)
The ethics objective structured clinical examination (2007) (36)
Genomics—a global public good? (2003) (35)
Factors influencing agbiotech adoption and development in sub-Saharan Africa (2012) (35)
Five promising methods for health foresight (2010) (34)
South Korean biotechnology—a rising industrial and scientific powerhouse (2004) (34)
Ontario's formulary committee: how recommendations are made. (2003) (34)
The cancer specific advance directive (1998) (33)
A business plan to help the 'global South' in its fight against neglected diseases. (2009) (33)
What do hospital decision-makers in Ontario, Canada, have to say about the fairness of priority setting in their institutions? (2005) (33)
Decisions and care at the end of life (1995) (32)
Ethics of lung transplantation with live donors (1991) (32)
“The best places to die” (2003) (32)
Advancing the cause of advance directives. (1992) (32)
Bioethics for clinicians: 15. Quality end-of-life care. (1998) (32)
Consent to the publication of patient information (2004) (32)
Strengthening the role of ethics in medical education. (2003) (31)
Can a "good death" be made better?: A preliminary evaluation of a patient-centred quality improvement strategy for severely ill in-patients (2004) (30)
Access to adult liver transplantation in Canada: a survey and ethical analysis. (1996) (30)
South Africa: from species cradle to genomic applications (2008) (30)
Bioethics for clinicians: 5. Substitute decision-making. (1996) (30)
Access and use of human tissues from the developing world: ethical challenges and a way forward using a tissue trust (2011) (29)
Waiting Lists for Radiation Therapy: A Case Study (2001) (28)
A tough transition (2007) (28)
Bioethics for clinicians: 8. Confidentiality. (1997) (28)
An ethical pathway for gene editing. (2019) (28)
Accelerating Health Product Innovation in sub-Saharan Africa (2007) (28)
From diversity to delivery: the case of the Indian Genome Variation initiative (2008) (27)
Lessons on Ethical Decision Making from the Bioscience Industry (2006) (27)
The three main monotheistic religions and gm food technology: an overview of perspectives (2009) (27)
Priority Setting in Surgery: Improve the Process and Share the Learning (2003) (27)
Science-based health innovation in sub-Saharan Africa (2010) (27)
Stability of Treatment Preferences: Although Most Preferences Do Not Change, Most People Change Some of Their Preferences (1997) (27)
South Africa: from species cradle to genomic applications (2009) (26)
Harnessing biodiversity: the Malagasy Institute of Applied Research (IMRA) (2010) (26)
Hospital policies on life-sustaining treatments and advance directives in Canada. (1994) (26)
Bioethics for clinicians: 11. Euthanasia and assisted suicide. (1997) (26)
Healthcare sustainability and the challenges of innovation to biopharmaceuticals in Canada. (2008) (26)
Legal and Ethical Approaches to Stem Cell and Cloning Research: A Comparative Analysis of Policies in Latin America, Asia, and Africa (2004) (26)
BioIndustry Ethics (2005) (26)
What could infant and young child nutrition learn from sweatshops? (2011) (26)
Harnessing stem cells for health needs in India. (2008) (25)
Biotechnology patenting takes off in developing countries (2006) (25)
Venture funding for science-based African health innovation (2010) (25)
The incommensurability of research risks and benefits: practical help for research ethics committees. (1995) (25)
Research in Clinical Ethics (1990) (24)
Grand Challenges in Global Health: Ethical, Social, and Cultural Issues Based on Key Informant Perspectives (2007) (24)
Addressing Ethical, Social, and Cultural Issues in Global Health Research (2013) (24)
The effect of advance care planning on completion of advance directives and patient satisfaction in people with HIV/AIDS (2000) (23)
Health biotechnology publishing takes-off in developing countries (2006) (23)
Bidil: recontextualizing the race debate (2008) (22)
Innovative drugs and vaccines in China, India and Brazil (2012) (22)
Science, Society, and the Supermarket: The Opportunities and Challenges of Nutrigenomics (2006) (22)
Ethics of resource allocation: dimensions for healthcare executives. (1998) (22)
"Harnessing genomics to improve health in Africa" – an executive course to support genomics policy (2004) (22)
A Social Audit Model for Agro-biotechnology Initiatives in Developing Countries: Accounting for Ethical, Social, Cultural, and Commercialization Issues (2009) (21)
Indian vaccine innovation: the case of Shantha Biotechnics (2011) (21)
Biotechnology to improve health in developing countries -- a review. (2004) (21)
Long‐Term Care Facility Policies on Life‐Sustaining Treatments and Advance Directives in Canada (1994) (20)
Resource allocation: beyond evidence-based medicine and cost-effectiveness analysis. (1997) (20)
A randomized trial of teaching bioethics to surgical residents. (2005) (20)
What does Cruzan mean to the practicing physician? (1991) (20)
Africa's largest long-lasting insecticide-treated net producer: lessons from A to Z Textiles (2010) (20)
Stagnant Health Technologies in Africa (2010) (20)
Strengthening the Role of Genomics in Global Health (2004) (20)
Assessing competency to address ethical issues in medicine (1991) (20)
SDGs: start with maternal, newborn, and child health cluster (2014) (20)
Future Directions in Clinical Ethics (1991) (19)
Communicating advance directives from long-term care facilities to emergency departments. (2001) (19)
A survey of South-North health biotech collaboration (2009) (19)
Seasonal bed closures in an intensive care unit: a qualitative study. (2003) (18)
Regenerative medicine in Brazil: small but innovative. (2010) (18)
Universal health care, genomic medicine and Thailand: investing in today and tomorrow (2008) (17)
The ethics of the Global Kidney Exchange programme (2019) (17)
Evaluation of a multicenter ethics objective structured clinical examination (1994) (17)
Addressing conflicts of interest in Public Private Partnerships (2010) (17)
Just regionalisation: rehabilitating care for people with disabilities and chronic illnesses (2006) (16)
Elective use of life-sustaining treatments in internal medicine. (1991) (16)
The road to commercialization in Africa: lessons from developing the sickle-cell drug Niprisan (2010) (16)
Shared Principles of Ethics for Infant and Young Child Nutrition in the Developing World (2010) (16)
Science-based health innovation in Ghana: health entrepreneurs point the way to a new development path (2010) (15)
Grand challenges in humanitarian aid (2018) (14)
Corporate social responsibility strategies aimed at the developing world: perspectives from bioscience companies in the industrialised world (2006) (14)
Ontario’s Formulary Committee (2012) (14)
Proxy, Health, and Personal Care Preferences: Implications for End-of-Life Care (1999) (14)
Advance directives in dialysis. (1994) (14)
Advance directives in family practice. (1993) (13)
Better governance in academic health sciences centres: moving beyond the Olivieri/Apotex Affair in Toronto (2004) (13)
The emergence of Egyptian biotechnology from generics (2004) (13)
Accountability Agreements in Ontario Hospitals: Are They Fair? (2006) (13)
Nancy B.: the criminal code and decisions to forgo life-sustaining treatment. (1992) (13)
Human genomic variation initiatives in emerging economies and developing countries (2008) (13)
Bridging the Genomics Divide (2003) (13)
The role of the domestic private sector in developing countries for addressing local health needs (2006) (12)
Transatlantic divide in publication of content relevant to developing countries (2004) (12)
Can incubators work in Africa? Acorn Technologies and the entrepreneur-centric model (2010) (12)
Science-based health innovation in Uganda: creative strategies for applying research to development (2010) (12)
Global health or global wealth? (2010) (12)
The case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries (2011) (11)
Quality end-of-life care: where do we go from here? (2000) (11)
Is there an ethical obligation to complete polio eradication? (2010) (11)
Advance Directives in Palliative Care (1994) (11)
Science-based health innovation in Tanzania: bednets and a base for invention (2010) (10)
Nephrologists' Experience with and Attitudes Towards Decisions To Forego Dialysis1 (1992) (10)
A Visual Dashboard for Moving Health Technologies From “Lab to Village” (2007) (10)
A focus on child development (2014) (9)
Realising the promise of genomics: exploring governance (2006) (9)
GENOMICS, BIOTECHNOLOGY AND GLOBAL HEALTH: THE WORK OF THE UNIVERSITY OF TORONTO JOINT CENTRE FOR BIOETHICS (2004) (9)
Human-animal chimeras for vaccine development: an endangered species or opportunity for the developing world? (2010) (9)
Outcome rates for individual surgeons: concerns about accuracy, completeness, and consequences of disclosure. (1994) (9)
Continuing Problems with Patient Self-Determination (1993) (9)
Innovating for women’s, children’s, and adolescents’ health (2015) (8)
Turning science into health solutions: KEMRI’s challenges as Kenya’s health product pathfinder (2010) (8)
Medical journals are dead. Long live medical journals. (2000) (8)
Computer Searches of the Medical Ethics Literature (1990) (8)
"Harnessing genomics to improve health in India" – an executive course to support genomics policy (2004) (8)
Sex, gender, and health biotechnology: points to consider (2009) (8)
The Cambridge Textbook of Bioethics: Priority setting (2008) (8)
Should doctors kill patients? (1988) (7)
Group Report: Developing an Eradication Investment Case (2011) (7)
Globetrotting firms: Canada's health biotechnology collaborations with developing countries (2009) (7)
Tiny technologies for the global good (2005) (7)
Genomics and Global Health - A Report of the Genomics Working Group of the Science and Technology Task Force of the United Nations Millennium Project (2004) (7)
Nutrients and Norms: Ethical Issues in Nutritional Genomics (2006) (7)
Franchising Rabies Vaccine Delivery: The Case of Indian Immunologicals (2011) (6)
Bioethics for clinicians: Advance care planning (2005) (6)
Case study: India's billion dollar biotech (2010) (6)
Which advance directive do patients prefer? (2007) (6)
North–South partnerships—a study of Canadian firms (2007) (6)
How Biodevelopment can Enhance Biosecurity (2009) (6)
Priority-setting decisions for new cancer drugs (2002) (6)
The case of Nancy Cruzan, the Patient Self-Determination Act and advance directives in Canada. (1991) (5)
Venture capital on a shoestring: Bioventures’ pioneering life sciences fund in South Africa (2010) (5)
In Global Health Research, Is It Legitimate To Stop Clinical Trials Early on Account of Their Opportunity Costs? (2009) (5)
Do Patents Encourage or Inhibit Genomics as a Global Public Good? (2003) (5)
Applying genomics-related technologies for Africa's health needs. (2007) (5)
Innovation Cultures in Developing Countries: The Case of Health Biotechnology (2007) (5)
Science-based health innovation in Rwanda: unlocking the potential of a late bloomer (2010) (5)
Guidance for reconciling patent rights and disclosure of findings at scientific meetings (2010) (5)
Withdrawal from dialysis: an ethical perspective. (1988) (5)
Different Rhythms of Health Biotechnology Development in Brazil and Cuba (2006) (5)
The "Supremes" decide on assisted suicide: what should a doctor do? (1997) (5)
Getting governance into genomics (2005) (4)
The Cambridge Textbook of Bioethics: Teaching bioethics to medical students and postgraduate trainees in the clinical setting (2008) (4)
Wounded Souls: The Need for Child Protection Professionals and Faith Leaders to Recognize and Respond to the Spiritual Impact of Child Abuse (2019) (4)
Bridging the Genomics Divide. (Global Insights) (2003) (4)
Harnessing genomics to improve health in the Eastern Mediterranean Region – an executive course in genomics policy (2005) (4)
The grandest challenge : bringing life-saving science from lab to village (2011) (4)
Global Health and Global Health Ethics: Global health ethics: the rationale for mutual caring (2011) (4)
Increasing human security through biotechnology (2006) (4)
Bone marrow transplant for rheumatoid arthritis: the costs of a cure. (1999) (4)
Aid to Capacity Evaluation (2016) (3)
Ontario's proposed consent laws: 1. Consent and capacity, substitute decisions, advance directives and emergency treatment. (1992) (3)
Legalized active euthanasia: an Aesculapian tragedy. (1989) (3)
Innovation for development (2013) (3)
Isolationism is not the answer to bioterrorism (2002) (3)
Bioethics for clinicians: continuing the series. (2000) (3)
Coordinating Pastoral Care of Survivors with Mental Health Providers (2018) (3)
Commentary: learning to love mistakes. (2001) (2)
Beyond GM Foods: Genomics, Biotechnology and Global Health Equity (2005) (2)
Motivating action: why should Canadian physicians participate in research, education, or patient care in the developing world? (2007) (2)
AFFYMETRIX, INC.: USING CORPORATE ETHICS ADVICE (2005) (2)
DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPS (2005) (2)
Ethical considerations in liver transplantation. (1994) (2)
The Global Kidney Exchange programme – Authors' reply (2020) (2)
The IVI ’ s innovative approach to closing the gap between vaccines for industrialized and developing countries (2010) (2)
MERCK: STAYING THE COURSE (2005) (2)
Teaching bioethics in the clinical setting (2)
Erratum: South-South entrepreneurial collaboration in health biotech (2010) (2)
Bill C-203: a postmortem analysis of the "right-to-die" legislation that died. (1993) (2)
Enabling knowledge societies in developing countries: the example of genomics (2006) (2)
Euthanasia and End-of-Life Care—Reply (1999) (1)
Genomic Applications in Medicine and Health in India (2012) (1)
Improving the Quality of Health Care for Patients through Clinical Medical Ethics Education (2017) (1)
Qualitative Research on End-of-Life Care: Unrealized Potential (2010) (1)
SCIONA LTD.: A PIONEER IN NUTRIGENOMICS: THE PATH TO CONSUMER ACCEPTANCE (2005) (1)
Symposium: teaching and learning clinical medical ethics during residency training. (1988) (1)
Vision is needed to address problem of global health information (2001) (1)
GENZYME: PUTTING PATIENTS FIRST (2005) (1)
Ontario's proposed consent laws: 2. Advocacy. (1992) (1)
Minimal refereeing will lead to global equity of information (2001) (1)
Indian vaccine innovation : the case of Shantha (2011) (1)
The ELSI Genetics Regulatory Resource Kit: A Tool for Policymakers in Developing Countries (2004) (1)
Harnessing Genomics for Global Health: The Role of Higher Education (2005) (1)
A New Model of Advance Care Planning (2016) (1)
HIV-seropositive surgeons: informed consent and public health policy. (1992) (1)
Erratum: Factors influencing agbiotech adoption and development in sub-Saharan Africa (2012) (1)
Contributors (1991) (0)
Champions for children. State of the worlds mothers 2011. Essays on why investments in maternal and child health care in developing countries are good for America. (2011) (0)
Responding to Child Abuse During a Pandemic (2021) (0)
. Genomics for Universal Healthcare in Thailand1,2 (2012) (0)
Is it ethical to forgo treatment (1997) (0)
Nutrigenomics and the Regulation of Health Claims for Foods and Drugs (2006) (0)
Chemical weapons: safe until 2004? (1995) (0)
BOLD IDEAS WITH BIG IMPACT (2016) (0)
Science and society - Universal health care, genomic medicine and Thailand: investing in today and tomorrow (2008) (0)
Cross border shopping: how much for your heart? (2006) (0)
MONSANTO COMPANY: BIO-AGRICULTURE PIONEER (2005) (0)
Harnessing Advanced Technologies for Global Health Equity (2008) (0)
Regenerative Medicine and the Developing (2006) (0)
Information Systems for Patient Follow-Up and Chronic Management of HIV and Tuberculosis: A Life-Saving Technology in Resource-Poor Areas (e29) (2018) (0)
Financial impact of liver transplant surgery (Reply) (1990) (0)
Patients' motivations for physician-assisted suicide (2002) (0)
The Science of Nutrigenomics and Nutrigenetics (2006) (0)
Debatechimeras for vaccine development: an endangered species or opportunity for the developing world? (2010) (0)
Address from the trustees appointed by the Committee of Management for Bettering the Condition of the Poor (0)
Replenishment of the Global Fund: global solidarity needed (2016) (0)
Authors' reply [4] (2006) (0)
TGN BIOTECH: A START-UP WITH ETHICAL ROOTS (2005) (0)
Nutritional Genomics: Opportunities and Challenges (2006) (0)
Developing a new model for transmitting advance directives from long-term care facilities to emergency departments (1999) (0)
The Ethics of Nutrigenomic Tests and Information (2006) (0)
PHARMASNPS INC.: CREATING AN ETHICS ADVISORY BOARD (2005) (0)
South Africa—blazing a trail for African (2004) (0)
Commercialization of Health Products from Sub-Saharan Africa: Challenges and Opportunities (2011) (0)
Healthcare Venture Capital for Africa—Response (2011) (0)
Canada's global health role (2018) (0)
Authors' Reply (2006) (0)
A Shadow Falls (2009) (0)
Cost savings at the end of life. (1994) (0)
NOVO NORDISK: THE TRIPLE BOTTOM LINE (2005) (0)
Peter A Singer on behalf of the BMJ Ethics Committee Sometimes valuable clinical information cannot be published because it is not possible to contact patients to obtain consent. The BMJ therefore asked its ethics committee to review the guidelines on (2004) (0)
MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUES (2005) (0)
Alternatives for Nutrigenomic Service Delivery (2006) (0)
10 Thompson Grp1.indd (2011) (0)
CONCLUSION: LESSONS FOR COMPANIES AND FUTURE ISSUES (2005) (0)
WHEN TO USE ADVANCE TREATMENT DIRECTIVES. AUTHOR'S REPLY (1992) (0)
PIPELINE BIOTECH A/S: COMPETING REGULATORY REGIMES FOR LABORATORY ANIMAL EXPERIMENTS (2005) (0)
EUTHANASIA DEBATE. AUTHOR'S REPLY (1990) (0)
Resource allocation in coronary revascularization. (1997) (0)
INTERLEUKIN GENETICS AND ALTICOR: AN UNLIKELY PARTNERSHIP (2005) (0)
P64 Instrument development: Rolls-Royce versus Volkswagen (1993) (0)
The Development Innovation Fund in Health - final technical report (2017) (0)
A survey of entrepreneurial collaborations among health biotech firms in developing countries reveals a surprisingly high level of collaboration but a lack of emphasis on new or improved health biotech products and processes. (2010) (0)
Nutrigenomics: Justice, Equity, and Access (2006) (0)
A Tool for Policymakers in Developing Countries (2004) (0)
Science-based health innovation in (2010) (0)
advance care planning. Autonomy, liberalism and (2008) (0)
Mental Health and Healthcare System Responses to Adolescent Maltreatment (2021) (0)
Recognizing and Responding to the Spiritual Impact of Child Abuse (2021) (0)
MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUES (2005) (0)
Grand challenges in humanitarian aid (2018) (0)
Legislated rights advice: a cautionary tale. (1998) (0)
A resident’s view (2011) (0)
Debateconflicts of interest in Public Private Partnerships (2010) (0)
Deeper lessons from the CMAJ debacle (2006) (0)
BMC Public Health Correspondence Public engagement on global health challenges (2008) (0)

This paper list is powered by the following services:

Other Resources About Peter A. Singer

en.wikipedia.org

What Schools Are Affiliated With Peter A. Singer?

Peter A. Singer is affiliated with the following schools:

Peter A. Singer's Academic­Influence.com Rankings

Why Is Peter A. Singer Influential?

Peter A. Singer's Published Works

Published Works

Other Resources About Peter A. Singer

What Schools Are Affiliated With Peter A. Singer?

Peter A. Singer's AcademicInfluence.com Rankings